Neurology 2003;60:1234-1240
© 2003 American Academy of Neurology
Special Article
Neuroprotective agents for clinical trials in Parkinson’s disease
A systematic assessment
B.M. Ravina, MD,
S.C. Fagan, PharmD,
R.G. Hart, MD,
C.A. Hovinga, PharmD,
D.D. Murphy, PhD,
T.M. Dawson, MD PhD and
J.R. Marler, MD
From the National Institute of Neurological Disorders and Stroke (Drs. Ravina, Hart, Murphy, and Marler) National Institutes of Health, Rockville, MD; Department of Pharmacology (Dr. Fagan), Medical College of Georgia, Augusta; Departments of Pharmacy and Neurology (Dr. Hovinga), Cleveland Clinic Foundation, OH; and Johns Hopkins University School of Medicine (Dr. Dawson), Baltimore, MD.
Address correspondence to Dr. Bernard M. Ravina, NINDS, Neuroscience Center, Rm 2225, 6001 Executive Blvd, Rockville, MD 20892-9257; e-mail: RavinaB{at}ninds.nih.gov
Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials.
Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood–brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria.
Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD.
Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.
This article has been cited by other articles:
|
|
|
|
 
X. Zhou, X. Zhuo, F. Xie, K. Kluetzman, Y.-Z. Shu, W. G. Humphreys, and X. Ding
Role of CYP2A5 in the Clearance of Nicotine and Cotinine: Insights from Studies on a Cyp2a5-null Mouse Model
J. Pharmacol. Exp. Ther.,
February 1, 2010;
332(2):
578 - 587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hayakawa, K. Mishima, M. Nozako, M. Hazekawa, S. Mishima, M. Fujioka, K. Orito, N. Egashira, K. Iwasaki, and M. Fujiwara
Delayed Treatment With Minocycline Ameliorates Neurologic Impairment Through Activated Microglia Expressing a High-Mobility Group Box1-Inhibiting Mechanism
Stroke,
March 1, 2008;
39(3):
951 - 958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Ahlskog
I can't get no satisfaction: Still no neuroprotection for Parkinson disease
Neurology,
October 9, 2007;
69(15):
1476 - 1477.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zhang, V. Anantharam, A. Kanthasamy, and A. G. Kanthasamy
Neuroprotective Effect of Protein Kinase C{delta} Inhibitor Rottlerin in Cell Culture and Animal Models of Parkinson's Disease
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
913 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ritz, A. Ascherio, H. Checkoway, K. S. Marder, L. M. Nelson, W. A. Rocca, G. W. Ross, D. Strickland, S. K. Van Den Eeden, and J. Gorell
Pooled Analysis of Tobacco Use and Risk of Parkinson Disease
Arch Neurol,
July 1, 2007;
64(7):
990 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mitsumoto
Mitochondrial Nutrition as a Strategy for Neuroprotection in Parkinson's Disease--Research Focus in the Department of Alternative Medicine and Experimental Therapeutics at Hokuriku University
Evid. Based Complement. Altern. Med.,
June 1, 2007;
4(2):
263 - 265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Tilley and W. R. Galpern
Screening Potential Therapies: Lessons Learned From New Paradigms Used in Parkinson Disease
Stroke,
February 1, 2007;
38(2):
800 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bender, W. Koch, M. Elstner, Y. Schombacher, J. Bender, M. Moeschl, F. Gekeler, B. Muller-Myhsok, T. Gasser, K. Tatsch, et al.
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial.
Neurology,
October 10, 2006;
67(7):
1262 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, L. Curatolo, P. Salvati, and R. G. Fariello
Safinamide: from molecular targets to a new anti-Parkinson drug.
Neurology,
October 10, 2006;
67(7 Suppl 2):
S18 - S23.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. J. Traynor, L. Bruijn, R. Conwit, F. Beal, G. O'Neill, S. C. Fagan, and M. E. Cudkowicz
Neuroprotective agents for clinical trials in ALS: A systematic assessment.
Neurology,
July 11, 2006;
67(1):
20 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kieburtz
Issues in neuroprotection clinical trials in Parkinson's disease
Neurology,
May 23, 2006;
66(10_suppl_4):
S50 - S57.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. A. Hauser and T. A. Zesiewicz
Clinical trials aimed at detecting neuroprotection in Parkinson's disease
Neurology,
May 23, 2006;
66(10_suppl_4):
S58 - S68.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. W. Olanow
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease
Neurology,
May 23, 2006;
66(10_suppl_4):
S69 - S79.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. J. Chen and A.-V. Ly
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease
Am. J. Health Syst. Pharm.,
May 15, 2006;
63(10):
915 - 928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Tilley, Y. Y. Palesch, K. Kieburtz, B. Ravina, P. Huang, J. J. Elm, K. Shannon, G. F. Wooten, C. M. Tanner, G. C. Goetz, et al.
Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs
Neurology,
March 14, 2006;
66(5):
628 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The NINDS NET-PD Investigators
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
Neurology,
March 14, 2006;
66(5):
664 - 671.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Xu, Y. Xu, D. Brown-Jermyn, J.-F. Chen, A. Ascherio, D. E. Dluzen, and M. A. Schwarzschild
Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
J. Neurosci.,
January 11, 2006;
26(2):
535 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Guimaraes, K. Kieburtz, C. G Goetz, J. J Elm, Y. Y Palesch, P. Huang, B. Ravina, C. M Tanner, and B. C Tilley
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
Clinical Trials,
December 1, 2005;
2(6):
509 - 518.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. G. Nutt and G. F. Wooten
Diagnosis and Initial Management of Parkinson's Disease
N. Engl. J. Med.,
September 8, 2005;
353(10):
1021 - 1027.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Chen and D. M. Swope
Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease
J. Clin. Pharmacol.,
August 1, 2005;
45(8):
878 - 894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Levy, E. D. Louis, L. Cote, M. Perez, H. Mejia-Santana, H. Andrews, J. Harris, C. Waters, B. Ford, S. Frucht, et al.
Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease
Arch Neurol,
March 1, 2005;
62(3):
467 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ascherio, M. G. Weisskopf, E. J. O'Reilly, M. L. McCullough, E. E. Calle, C. Rodriguez, and M. J. Thun
Coffee Consumption, Gender, and Parkinson's Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen
Am. J. Epidemiol.,
November 15, 2004;
160(10):
977 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. LeWitt
Clinical trials of neuroprotection for Parkinson's disease
Neurology,
October 12, 2004;
63(7_suppl_2):
S23 - S31.
[Full Text]
|
|
|
|
|
|
|
E. Diguet, C. E. Gross, E. Bezard, F. Tison, N. Stefanova, G. K. Wenning, B. Ravina, S. Fagan, R. Hart, C. Hovinga, et al.
Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
Neurology,
January 13, 2004;
62(1):
158 - 159.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Shults
Treatments of Parkinson Disease: Circa 2003
Arch Neurol,
December 1, 2003;
60(12):
1680 - 1684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Feigin
Nondopaminergic symptomatic therapies for Parkinson's disease: Turn on or turn off?
Neurology,
August 12, 2003;
61(3):
286 - 287.
[Full Text]
[PDF]
|
|
|
Correspondence:
Read all Correspondence
- Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment
- F Tison, et al.
- Neurology Online, 1 Jul 2003
[Full text]
- Reply to Letter to the Editor
- Bernard Ravina, et al.
- Neurology Online, 1 Jul 2003
[Full text]
|
